Dolores Isla

19.8k total citations · 1 hit paper
202 papers, 5.1k citations indexed

About

Dolores Isla is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Dolores Isla has authored 202 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 126 papers in Oncology, 125 papers in Pulmonary and Respiratory Medicine and 40 papers in Molecular Biology. Recurrent topics in Dolores Isla's work include Lung Cancer Treatments and Mutations (111 papers), Lung Cancer Research Studies (64 papers) and Lung Cancer Diagnosis and Treatment (48 papers). Dolores Isla is often cited by papers focused on Lung Cancer Treatments and Mutations (111 papers), Lung Cancer Research Studies (64 papers) and Lung Cancer Diagnosis and Treatment (48 papers). Dolores Isla collaborates with scholars based in Spain, United States and France. Dolores Isla's co-authors include Rafael Rosell, Carlos Camps, Miquel Tarón, Enriqueta Felip, José Javier Sánchez, Bartomeu Massutí, Mariano Provencio, Á. Artal, Manuel Cobo and Luis Paz‐Ares and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Lancet Oncology.

In The Last Decade

Dolores Isla

196 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

2015 324 citations Enriqueta Felip, Manuel Cobo et al. profile →

Peers

Countries citing papers authored by Dolores Isla

Since Specialization

Citations

This map shows the geographic impact of Dolores Isla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dolores Isla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dolores Isla more than expected).

Fields of papers citing papers by Dolores Isla

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dolores Isla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dolores Isla. The network helps show where Dolores Isla may publish in the future.

Co-authorship network of co-authors of Dolores Isla

This figure shows the co-authorship network connecting the top 25 collaborators of Dolores Isla. A scholar is included among the top collaborators of Dolores Isla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dolores Isla. Dolores Isla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Germline Mutation Analysis and Real-World Impact in a Selected Cohort of Patients with Non-Small Cell Lung Cancer: INHERITY LC Study 2025 ·Clinical Lung Cancer ·(unknown), (unknown), Laura Mezquita, Oliver Higuera, Sebastián Menao, María Pilar Arruebo, Javier Torres-Jiménez, Javier de Castro, Dolores Isla, (unknown)	0
2	Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne Liquid CDx: a cost-effectiveness analysis 2024 ·Journal of Medical Economics ·Dolores Isla, Rosa Álvarez, María José Domper-Arnal, Edurne Arriola, Aitor Azkárate, (unknown), (unknown), Pilar Garrido, Ernest Nadal, Ana Laura Ortega Granados, (unknown), María J. Crespo, (unknown), (unknown), Reyes Bernabé	3
3	Biomarkers of Immunotherapy Response in Patients with Non-Small-Cell Lung Cancer: Microbiota Composition, Short-Chain Fatty Acids, and Intestinal Permeability 2024 ·Cancers ·(unknown), (unknown), (unknown), (unknown), (unknown), Ariel Ramírez-Labrada, Luis Martínez‐Lostao, María Pilar Domingo, (unknown), Alfonso Yubero, (unknown), (unknown), José Ramón Paño, (unknown), Julián Pardo, Dolores Isla, Rosa del Campo, Eva M. Gálvez	6
4	PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement 2023 ·Journal of Clinical Medicine ·Dolores Isla, (unknown), J. Casal, Manuel Cobo, Margarita Majem, Noemı́ Reguart, Jon Zugazagoitia, Reyes Bernabé	6
5	A Subset of PD-1-Expressing CD56bright NK Cells Identifies Patients with Good Response to Immune Checkpoint Inhibitors in Lung Cancer 2023 ·Cancers ·(unknown), Ariel Ramírez-Labrada, (unknown), Luis Martínez‐Lostao, José Ramón Paño‐Pardo, (unknown), (unknown), (unknown), (unknown), (unknown), Alfonso Yubero, María Pilar Domingo, (unknown), Eva M. Gálvez, Julián Pardo, Dolores Isla	12
6	Risk factors for cancer-related cognitive impairment in breast and colorectal cancer patients who undergo chemotherapy 2023 ·SHILAP Revista de lepidopterología ·Patricia Iranzo, Ana Callejo, (unknown), Sebastián Menao, Dolores Isla, Raquel Andrés	2
7	New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology 2022 ·Clinical & Translational Oncology ·Dolores Isla, María D. Lozano, Luis Paz‐Ares, Clara Salas, Javier de Castro, Esther Conde, Enriqueta Felip, Javier Gómez‐Román, Pilar Garrido, Ana B. Enguita	23
8	Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO) 2022 ·Lung Cancer ·Benjamin Levy, Fabrice Barlési, Luis Paz‐Ares, Jaafar Bennouna, Mustafa Erman, Enriqueta Felip, Dolores Isla, Hye Ryun Kim, Sang‐We Kim, J. Madelaine, Olivier Molinier, Mustafa Özgüroğlu, Delvys Rodríguez‐Abreu, Abidemi Adeniji, Robert M. Lorence, Isabelle Voccia, Michael Chisamore, Jonathan W. Riess	6
9	PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis 2021 ·Journal of Clinical Medicine ·Margarita Majem, Manuel Cobo, Dolores Isla, Diego Márquez-Medina, Delvys Rodríguez‐Abreu, Joaquín Casal‐Rubio, (unknown), Reyes Bernabé, (unknown), (unknown), (unknown), Luis Paz‐Ares	15
10	Intratumoral versus Circulating Lymphoid Cells as Predictive Biomarkers in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Is the Easiest Path the Best One? 2020 ·Cells ·(unknown), Dolores Isla, (unknown), Eva M. Gálvez, (unknown), (unknown), José Ramón Paño, Ariel Ramírez-Labrada, (unknown), (unknown), Alfonso Yubero, Julián Pardo, Luis Martínez‐Lostao	16
11	SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019) 2020 ·Clinical & Translational Oncology ·Manuel Dómine, Teresa Morán, Dolores Isla, Juan Luis Gomez Marti, Ivana Sullivan, Mariano Provencio, M.E. Olmedo, Santiago Ponce, Ana Blasco, Manuel Cobo	40
12	Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus 2020 ·Clinical & Translational Oncology ·Dolores Isla, Javier de Castro, Rosario García‐Campelo, Margarita Majem, David Vicente, Óscar Juan	1
13	From Tumor Mutational Burden to Blood T Cell Receptor: Looking for the Best Predictive Biomarker in Lung Cancer Treated with Immunotherapy 2020 ·Cancers ·(unknown), Julián Pardo, (unknown), Eva M. Gálvez, (unknown), Dolores Isla, Luis Martínez‐Lostao, (unknown), José Ramón Paño, (unknown), Ariel Ramírez-Labrada, (unknown), Alfonso Yubero, (unknown), (unknown)	20
14	Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer 2019 ·European Journal of Cancer Care ·Eva Ciruelos, (unknown), Dolores Isla, Rafael López‐López, Reyes Bernabé, Encarnación González‐Flores, Beatriz Cirauqui, (unknown), Serafín Morales, Alberto Arcediano, I. Barneto, Pablo Cerezuela, José Juan Illarramendi, Cristina Morales, Santiago Ponce	19
15	Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus 2019 ·Clinical & Translational Oncology ·Dolores Isla, Javier de Castro, Rosario García‐Campelo, P. Lianes, Enriqueta Felip, Pilar Garrido, Luis Paz‐Ares, José Trigo	11
16	Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database 2017 ·Clinical & Translational Oncology ·Jordi Remón, Dolores Isla, Pilar Garrido, Javier de Castro, Margarita Majem, Núria Viñolas, Á. Artal, Enric Carcereny, M.R. García-Campelo, P. Lianes, Mariano Provencio, Óscar Juan, Pilar Díz, Ricardo Blanco, Rafael López Castro, I. Maestu, Catalina Vadell, Enriqueta Felip	4
17	Efficacy and Safety Results From a Phase 2, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy in Advanced Squamous-Cell Non-Small Cell Lung Cancer (sq NSCLC) 2014 ·International Journal of Radiation OncologyBiologyPhysics ·Fred R. Hirsch, Ramaswamy Govindan, Zanete Zvirbule, Fadi Braiteh, Achim Rittmeyer, Cristóbal Belda-Iniesta, Dolores Isla, Thomas M. Cosgriff, Michelle Boyer, Mikio Ueda, Sem H. Phan, David R. Gandara	2
18	Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression 2014 ·Lung Cancer ·Noemı́ Reguart, Rafael Rosell, Felipe Cardenal, Andrés F. Cardona, Dolores Isla, Ramón Palmero, Teresa Morán, Christian Rolfo, (unknown), Amelia Insa, Enric Carcereny, Margarita Majem, Javier de Castro, Cristina Queralt, Miguel Ángel Molina‐Vila, Miquel Tarón	72
19	MO19390 (SAiL): Bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC 2012 ·Lung Cancer ·Éric Dansin, Saverio Cinieri, Pilar Garrido, Frank Griesinger, Dolores Isla, (unknown), Martin Kohlhäeufl	25
20	SEOM clinical guidelines for the treatment of advanced colorectal cancer 2010 ·Clinical & Translational Oncology ·Rocio García‐Carbonero, (unknown), (unknown), Vicente Alonso Orduña, Andrés Cervantes, Javier Gállego, Pilar Alfonso, (unknown), Encarnación González‐Flores, María Lomas Garrido, Dolores Isla	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact